Mini Enzyme Moves Gene Editing Closer to the Clinic
By Heidi Ledford,
Nature News
| 04. 01. 2015
Untitled Document
A tweak to a technique that edits DNA with pinpoint precision has boosted its ability to correct defective genes in people. Called CRISPR, the method is already used in the lab to insert and remove genome defects in animal embryos. But the genetic instructions for the machinery on which CRISPR relies — a gene-editing enzyme called Cas9 and RNA molecules that guide it to its target — are simply too large to be efficiently ferried into most of the human body’s cells.
This week, researchers report a possible way around that obstacle: a Cas9 enzyme that is encoded by a gene about three-quarters the size of the one currently used. The finding, published on 1 April in Nature, could open the door to new treatments for a host of genetic maladies (F. A. Ran et al. Nature http://dx.doi.org/10.1038/nature14299; 2015).
“There are thousands of diseases in humans associated with specific genetic changes,” says David Liu, a chemical biologist at Harvard University in Cambridge, Massachusetts, who was not involved in the latest study. “A fairly large fraction of those...
Related Articles
By Abby McCloskey, The Dallas Morning News | 10.10.2025
We Texans like to do things our way — leave some hide on the fence rather than stay corralled, as goes a line in Wallace O. Chariton’s Texas dictionary This Dog’ll Hunt. Lately, I’ve been wondering what this ethos...
By Jay S. Kaufman, Los Angeles Review of Books | 09.27.2025
This is the 10th installment in the Legacies of Eugenics series, which features essays by leading thinkers devoted to exploring the history of eugenics and the ways it shapes our present. The series is organized by Osagie K. Obasogie in...
By Julia Black, MIT Technology Review | 10.16.2025
Consider, if you will, the translucent blob in the eye of a microscope: a human blastocyst, the biological specimen that emerges just five days or so after a fateful encounter between egg and sperm. This bundle of cells, about the size of...
By Meagan Parrish, PharmaVoice | 10.10.2025
When CEO Ben Lamm steps into the spotlight, it’s usually to talk about his efforts bringing extinct animals back to life. Once a far-flung idea, Lamm and the company he heads, Colossal Biosciences, have proven they can pull it off...